India unveils world's first nasal vaccine for Covid (Photo for representation)
The booster dose of Bharat Biotech’s Covid-19 nasal vaccine iNCOVACC was given emergency use authorisation (EUA) by the Drugs Controller General of India (DCGI).
The EUA is reported to have been granted for restricted emergency use as the third dose for adults irrespective of having been administered Covaxin or Covishield vaccine doses.
According to the Hyderabad-based vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa.
iNCOVACC is India’s first nasal vaccine developed against Covid-19. The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.
The intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus. The booster dose will thereby protect against disease, infection, and transmission.
The Ministry of External Affairs (MEA) on Saturday strongly protested against recent allegations made by…
The Ministry of External Affairs on Saturday said that verification patrolling has commenced in Demchok…
The Ministry of External Affairs on Saturday reacted to the recent U.S. sanctions imposed on…
Two terrorists were killed by security forces during an encounter in Jammu and Kashmir's Anantnag…
Terming the recent terror attacks in Jammu and Kashmir as "unfortunate", Union Defence Minister Rajnath…
The Baloch Yakjehti Committee (BYC) held demonstrations against the ongoing enforced disappearances by the Pakistan…